NICE recommends use of Janssen ’s Imbruvica for Waldenstr ö m ’s macroglobulinaemia

The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Janssen Pharmaceutical ’s Imbruvica (ibrutinib) on the Cancer Drugs Fund (CDF) to treat adults with a type of   non-Hodgkin lymphoma called Waldenstr ö m ’s m…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news